Race Oncology
Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).
ASX Announcements
| Date | Title | |
|---|---|---|
| 13/03/2019 | Appendix 3B | Download |
| 27/02/2019 | Appendix 4D & Half-Year Financial Statements | Download |
| 25/02/2019 | Principal Investigator appointed for Bisantrene | Download |
| 14/02/2019 | Appendix 3Y-Dr William Garner | Download |
| 12/02/2019 | Change in substantial holding | Download |
| 12/02/2019 | Change of Director's Interest Notice-Mr Chris Ntoumenopoulos | Download |
| 12/02/2019 | Change of Director's Interest Notice-Dr William Garner | Download |
| 12/02/2019 | Change of Director's Interest Notice-Mr Peter Molloy | Download |
| 31/01/2019 | Race Receives $228k R&D Tax Incentive Refund | Download |
| 25/01/2019 | Appendix 4C - quarterly | Download |
ASX: RAC
Price
Latest News
Principal Investigator appointed for Bisantrene trial
Race Oncology is pleased to announce that Dr Roland Walter has agreed to be the Principal
Race appoints leading haematologist to support Bisantrene
Race Oncology is pleased to announce that it has executed a consulting agreement with Professor
Race reaches agreement with TrueMed for Bisantrene sales in Israel
Race Oncology is very pleased to announce that it has executed a Named Patient Program (NPP)
Don't miss important updates
Get the latest news & announcement and stay up-to-date.